Bedaquiline
- Generic Name
- Bedaquiline
- Brand Names
- Sirturo
- Drug Type
- Small Molecule
- Chemical Formula
- C32H31BrN2O2
- CAS Number
- 843663-66-1
- Unique Ingredient Identifier
- 78846I289Y
- Background
Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhi...
- Indication
Bedaquiline is indicated as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided.
...
- Associated Conditions
- Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
- Associated Therapies
- -
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 156
- Registration Number
- NCT05556746
- Locations
- 🇭🇹
GHESKIO, Port-au-Prince, Haiti
🇿🇦University of Cape Town, Cape Town, South Africa
Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 128
- Registration Number
- NCT05382312
- Locations
- 🇿🇦
GSK Investigational Site, Cape Town, South Africa
A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China
- Conditions
- Interventions
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 212
- Registration Number
- NCT05306223
- Locations
- 🇨🇳
Beijing Chest Hospital, Beijing, China
🇨🇳The Pulmonary Hospital of Fuzhou in Fujian Province（The tuberculosis control and prevention Hospital of Fuzhou in Fujian Province）, Fuzhou, China
🇨🇳The Eighth Medical Center of PLA General Hospital, Beijing, China
Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India
- Conditions
- Interventions
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Tuberculosis Research Centre, India
- Target Recruit Count
- 400
- Registration Number
- NCT05040126
- Locations
- 🇮🇳
S N Medical College, Agra, Uttarpradesh, India
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 89
- Registration Number
- NCT04717908
- Locations
- 🇨🇳
The Third People's Hospital of Shenzhen City, Shenzhen, Guangzhou, China
🇨🇳The Central Hospital of Wenzhou City, Wenzhou, Zhejiang, China
🇨🇳Hwa Mei Hosptal,University of Chinese Academy of Sciences(Ningbo No.2 Hospital), Ningbo, Zhejiang, China
A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 129
- Registration Number
- NCT04630145
- Locations
- 🇰🇷
Chonnam National University Hospital, Gwangju, Korea, Republic of
🇯🇵St. Luke's International Hospital, Chuo ku, Japan
🇯🇵Fukui Prefectural Hospital, Fukui-shi, Japan
Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- TASK Applied Science
- Target Recruit Count
- 22
- Registration Number
- NCT04629378
- Locations
- 🇿🇦
TASK Clinical Research Centre, Cape Town, Western Cape, South Africa
Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081
- Conditions
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
- Target Recruit Count
- 99
- Registration Number
- NCT04608955
- Locations
- 🇨🇳
Beijing Chest Hospital affiliated to Capital Medical University, Beijing, Beijing, China
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- The University of Queensland
- Target Recruit Count
- 300
- Registration Number
- NCT04310930
- Locations
- 🇦🇺
St George Hospital, Kogarah, New South Wales, Australia
🇦🇺Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺Royal Melbourne Hospital, Parkville, Victoria, Australia
Economic Evaluation of New MDR TB Regimens
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Medecins Sans Frontieres, Netherlands
- Target Recruit Count
- 73
- Registration Number
- NCT04207112
- Locations
- 🇿🇦
THINK Clinical Trial Unit, Hillcrest, Durban, KwaZulu-Natal, South Africa
🇿🇦King DinuZulu Hospital, Durban, KwaZulu-Natal, South Africa
🇧🇾Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital, Minsk, Belarus
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.